Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study
BackgroundCheckpoint inhibitor pneumonitis (CIP) is a rare but potentially fatal immune-related adverse event (irAE) that can interrupt immune checkpoint blockade in non-small cell lung cancer (NSCLC). With no validated pretreatment biomarkers and a di…